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Abstract
Background: Dyslipidemia, an increased level of total cholesterol (TC), triglycerides (TG), low-density-lipoprotein
cholesterol (LDL-C) and decreased level of high-density-lipoprotein cholesterol (HDL-C), is one of the most important
risk factors for cardiovascular disease. We examined the six-year trend of dyslipidemia in Newfoundland and Labrador
(NL), a Canadian province with a historically high prevalence of dyslipidemia.
Methods: A serial cross-sectional study on all of the laboratory lipid tests available from 2009 to 2014 was performed.
Dyslipidemia for every lipid component was defined using the Canadian Guidelines for the Diagnosis and Treatment of
Dyslipidemia. The annual dyslipidemia rates for each component of serum lipid was examined. A fixed and random
effect model was applied to adjust for confounding variables (sex and age) and random effects (residual variation in
dyslipidemia over the years and redundancies caused by individuals being tested multiple times during the study
period).
Results: Between 2009 and 2014, a total of 875,208 records (mean age: 56.9 ± 14.1, 47.6% males) containing a lipid
profile were identified. The prevalence of HDL-C and LDL-C dyslipidemia significantly decreased during this period
(HDL-C: 35.8% in 2009 [95% CI 35.5-36.1], to 29.0% in 2014 [95% CI: 28.8-29.2], P = 0.03, and LDL-C: 35.2% in 2009 [95%
CI: 34.9-35.4] to 32.1% in 2014 [95% CI: 31.9-32.3], P = 0.02). A stratification by sex, revealed no significant trend for any
lipid element in females; however, in men, the previously observed trends were intensified and a new decreasing trend
in dyslipidemia of TC was appeared (TC: 34.1% [95% CI 33.7-34.5] to 32.3% [95%CI: 32.0-32.6], p < 0.02, HDL-C:
33.8% (95%CI: 33.3-34.2) to 24.0% (95% CI: 23.7-24.3)], P < 0.01, LDL-C: 32.9% (95%CI:32.5-33.3) to 28.6 (95%CI:
28.3-28.9), P < 0.001). Adjustment for confounding factors and removing the residual noise by modeling the
random effects did not change the significance.
Conclusion: This study demonstrates a significant downward trend in the prevalence of LDL-C, HDL-C, and
TC dyslipidemia, exclusively in men. These trends could be the result of males being the primary target for
cardiovascular risk management.
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Background
Cardiovascular disease (CVD), remains to be the first
cause of death globally, with 17.7 million deaths each
year [1]. In Canada, over 1.3 million people have a diag-
nosis of heart disease [2], and CVD is the leading cause
of death (one-third of the total deaths) [3], imposing the
highest economic burden of disease after musculoskel-
etal conditions [2]. In the past decades, significant im-
provements have been reported in the rates of CVD and
its associated risk factors in the developed world. Over
the past 50 years, there has been a 70% decline in the in-
cidence of CVD in Canada [2]. Compared to the other
Canadian provinces, however, Newfoundland and Labra-
dor (NL) has the highest rates of CVD morbidity and
mortality in adults [4]. In 2007, Statistics Canada re-
ported that NL had the highest age-standardized mortal-
ity rate for major CVD events (218.5 per 100,000
population) among all Canadian provinces (national
average mortality rate: 151.9/100,000) [5]. This rate is
comparable to those of low- or middle-income nations
which tend to have higher CVD-related death rates com-
pared to the developed world [6, 7], and do not show a
declining trend in CVD incidence [8].
The declining global trends in CVD incidence has been
mainly attributed to decreasing rates of preventable CVD
risk factors such as tobacco use [9], uncontrolled hyper-
tension [10], and abnormal lipid levels [11]. Dyslipidemia,
defined as abnormally elevated levels of total cholesterol
(TC), low-density lipoprotein cholesterol (LDL-C), and tri-
glycerides (TG), as well as decreased levels of high-density
lipoprotein cholesterol (HDL-C), is one of the strongest
and most modifiable risk factors for CVD [12]. Like other
CVD risk factors, there has been an improvement in the
abnormal cholesterol levels among Canadians in the past
decade, and this trend is projected to continue over the
next few years [11]. However, it is not known whether the
declining trend in the prevalence of dyslipidemia has
reached the NL population. Our previous study demon-
strated that the prevalence of dyslipidemia, as represented
by abnormal levels of total cholesterol (40 vs. 37%), LDL-
C (29 vs. 25%), triglyceride (29 vs. 26%) and HDL-C (38
vs. 27%), is significantly higher in NL compared to the rest
of Canada [13]. Although the cultural and genetic isola-
tion of the NL population [14] might partially explain the
differences in the lipid profiles, our study on high-cardiac
risk patients has shown that primary care management,
particularly medication therapy, is the most contributing
factor to suboptimal lipid levels in Canada, and par-
ticularly, in NL [15]. Therefore, any change in the
pattern of dyslipidemia could well reflect the quality
of healthcare in the province, and thus, the higher
rates of CVD and dyslipidemia prevalence in NL ne-
cessitates the investigation of the trend of the change
in dyslipidemia.
The availability of Laboratory Information System
(LIS) in NL, which enables access to all of the laboratory
test results conducted in the province, provides an excel-
lent opportunity to investigate the rates of dyslipidemia
and its patterns over the past years. Discovery of this
trend in NL is essential since it can be helpful for the es-
timation of future prevalence of dyslipidemia and its
consequential burden on the health care system. Also,
these data are necessary for evaluation and monitoring
of the effectiveness of population- and community-wide
interventions in reducing the prevalence of dyslipidemia
and its adverse consequences in NL, and accordingly, in
Canada. The present study examines the trend and pat-
tern of dyslipidemia among the adult population living
in NL over a six-year period between 2009 and 2014.
Methods
Source of data
Individuals with a registered permanent address in NL
are provided with a lifetime medical care plan number.
For each laboratory service, the patient’s identification
(ID), date of service, and laboratory test results are en-
tered into the LIS. The system is administered through
four health region authorities in the province (Eastern,
Central, Western, and Labrador-Grenfell). The study ex-
tracted all available records included in the LIS between
January 2009 and December 2014. Every record con-
tained individual de-identified ID, age, sex, date of test-
ing, and lipid test results. Only records for individuals
who were 20 years and older at the time of lipid testing,
were used in this study.
Identification of trends of change in dyslipidemia
We defined dyslipidemia based on lipid levels, according
to the Canadian Guidelines for the Diagnosis and Treat-
ment of Dyslipidemia (Table 1), in effect during the time
of the study [16, 17]. The prevalence of dyslipidemia in
each year was calculated as the ratio of records with ab-
normal levels of lipid to the total number of records
available in that year. Descriptive statistics, including
mean and 95% confidence intervals (CI), were used to
describe and visualize the changes in the prevalence of
dyslipidemia over the 6-year period. A non-parametric
trend test was performed to examine the existence of a
changing trend in dyslipidemia during this time.
Table 1 Healthy levels of serum lipids for Canadian adults [3]
Lipid component Normal levels
Total cholesterol (TC) < 5.2 mmol/L
Triglycerides (TG) < 1.7 mmol/L
Low-density lipoprotein (LDL-C) cholesterol < 3.4 mmol/L
High-density lipoprotein (HDL-C) cholesterol Males > 1.0 mmol/L
Females > 1.3 mmol/L
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Adjustment for confounding factors and control for
repeated individual tests and random yearly variations
Assessment of the variability in the lipid profiles as re-
ported by the four different regional health authorities
was determined by measuring an intra-class correlation
which did not reveal a significant clustering by health re-
gion (not shown). Therefore this variable was not used
in this analysis. A multivariable logistic mixed effect
model was utilized to adjust for the confounding vari-
ables including age and sex, as well as to account for
variations caused by the same individuals repeating the
tests over the 6-year period or the normal yearly
changes. In this model, dyslipidemia status was consid-
ered as the response variable, the year was considered a
categorical predictor, and age and sex were incorporated
as confounding factors. The first year (2009) was consid-
ered as the base, to which all of the upcoming years
were compared. Given an individual could be tested for
lipid profile multiple times across the 6-year period, we
incorporated the individual ID as a random effect in the
model to account for this redundancy. As well, we incor-
porated the year variable as the second random effect to
reduce the residual variation that typically occurs on a
yearly basis in dyslipidemia rates. The analysis was con-
ducted using the lme4 package [18].
All of the statistical analyses were performed using R.
3.3.0. P-values less than 0.05 were considered significant.
Results
Characteristics of the study population
After quality assessment and removal of missing infor-
mation, a total of 875,208 records with lipid tests were
identified in LIS, representing the total number of tests
performed in the province between 2009 and 2014. A
considerable gradual increase in the number of tests was
noted from the first year (2009, ~ 115,000) to the last
year of the study (2014, ~ 184,000). The population was
almost equally composed of males and females with
slightly more records identified for women (52 - 53% fe-
males). The mean age ranged from 56 to 58 during the
6-year period. Table 2 represents the characteristics of
the study population as stratified by each year included
in our study.
Changes in the pattern of dyslipidemia between 2009 and
2014
Examination of the rates of dyslipidemia over the 6-year
period revealed a declining trend for HDL-C (35.8%
[95% confidence interval: 28.8 - 29.2] to 29.0% [95% con-
fidence interval: 28.8 - 29.2], p = 0.03) and LDL-C (35.2%
[95% confidence interval: 34.9 - 35.4] to 32.1% [95% con-
fidence interval: 31.9 - 32.3], p = 0.02). Other lipid com-
ponents fluctuated during the same period without
overall significant changes. Total cholesterol dyslipid-
emia, for instance, showed a decreasing trend from 39%
Table 2 Trends in dyslipidemia in Newfoundland and Labrador adults 2009-2014
2009 2010 2011 2012 2013 2014 P-value
Record count (% Males) 115,382 (48%) 134,710 (47%) 134,832 (47%) 143,322 (47%) 164,734 (48%) 182,228 (48%)
Age 56.0 (55.9-56.1) 55.8 (55.7-55.8) 56.2 (56.1-56.3) 56.5 (56.5-56.6) 57.7 (57.6-57.7) 58.3 (58.2-58.3)
TC dyslipidemia
Total 39.0 (38.7-39.3) 39.0 (38.7-39.3) 38.6 (38.3-38.9) 37.5 (37.2-37.7) 37.0 (36.7-37.2) 38.2 (38.0-38.4) 0.1
Female 43.5 (43.1-43.9) 43.2 (42.9-43.6) 43.3 (42.9-43.6) 42.2 (41.9-42.6) 41.7 (41.4-42.0) 43.6 (43.3-43.9) 0.5
Male 34.1 (33.7-34.5) 34.2 (33.9-34.6) 33.4 (33.1-33.8) 32.2 (31.9-32.6) 31.8 (31.5-32.1) 32.3 (32.0-32.6) 0.02*
HDL-C dyslipidemia
Total 35.8 (35.5-36.1) 32.6 (32.4-32.9) 30.3 (30.0-30.6) 32.8 (32.6-33.1) 30.0 (29.8-30.3) 29.0 (28.8-29.2) 0.03*
Female 37.5 (37.1-37.9) 35.2 (3.8-35.6) 33.7 (33.4-34.1) 36.6 (36.2-36.9) 34.6 (34.3-34.9) 33.4 (33.1-33.7) 0.2
Male 33.8 (33.3-34.2) 29.6 (29.2-30.0) 26.3 (26.0-26.7) 28.5 (28.1-28.8) 24.8 (24.5-25.1) 24.0 (23.7-24.3) 0.01*
LDL-C dyslipidemia
Total 35.2 (34.9-35.4) 33.7 (33.5-34.0) 32.5 (32.2-32.7) 32.5 (32.3-32.8) 31.2 (31.0-31.4) 32.1 (31.9-32.3) 0.02*
Female 37.2 (36.8-37.6) 35.5 (35.1-35.9) 34.5 (34.1-34.9) 35.1 (34.7-35.4) 33.7 (33.4-34.0) 35.3 (34.9-35.6) 0.2
Male 32.9 (32.5-33.3) 31.7 (31.3-32.1) 30.2 (29.9-30.6) 29.7 (29.3-30.1) 28.5 (28.1-28.8) 28.6 (28.3-28.9) 0.001*
TG dyslipidemia
Total 36.4 (36.1-36.6) 35.0 (34.8-35.3) 36.3 (36.1-36.6) 36.2 (35.9-36.4) 35.6 (35.3-35.8) 35.9 (35.6-36.1) 0.8
Female 34.1 (33.8-34.5) 32.9 (32.5-33.2) 34.1 (33.8-34.5) 34.0 (33.6-34.3) 33.6 (33.2-33.9) 34.1 (33.8-34.4) 0.7
Male 38.8 (38.4-39.2) 37.4 (37.0-37.8) 38.8 (38.4-39.2) 38.7 (38.3-39.1) 37.8 (37.4-38.1) 37.7 (37.4-38.1) 0.5
Age is presented as mean (95% confidence interval), and dyslipidemia is presented as Percentage (95% confidence interval). TC Total cholesterol, HDL-C High-
density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, TG Triglycerides
*Trend is significant at p < 0.05
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to 37% in 2013, but its rates increased to above 38% in
2014 (Fig. 1, Table 2). Re-examination of the trends fol-
lowing a split by sex, however, revealed that the declin-
ing pattern of change in HDL-C and LDL-C
dyslipidemia is only significant in males. The split also
resulted in the appearance of a significant decreasing
trend in total cholesterol dyslipidemia in males (34.1%
[95% confidence interval: 33.7 - 34.5] to 32.3% [95% con-
fidence interval: 32.0 - 32.6], p = 0.02), but not in females
(Table 2).
Trend of dyslipidemia after adjustment for confounding
factors and random effects
Using a multivariable logistic mixed effect model, we ex-
amined the yearly pattern of change as adjusted for con-
founding factors (age and sex) and random effects
(individuals repeating the test in the 6-year period, and
regular annual variations in dyslipidemia). The analysis
confirmed the previously observed declining rates of
dyslipidemia over the 6-year period with the most prom-
inent effect for HDL-C and LDL-C dyslipidemia. Ac-
cording to this analysis, the odds of finding an HDL-C
or LDL-C dyslipidemia in the laboratory test reports in
the last year of the study was significantly lower than
those in the first year (ORHDL-C: 0.78, 95% confidence
interval: 0.77 - 0.79, ORLDL-C: 0.87, 95% confidence
interval: 0.85 - 0.88). Although a declining trend was ob-
served for other lipid components, these findings were
not as prominent as those found for LDL-C and HDL-C,
with odds ratios ranging between 0.95 to 0.99. The most
determinant variable of dyslipidemia in the population,
however, was sex where males were significantly less
likely to have dyslipidemia of HDL-C, LDL-C, and total
cholesterol (OR: 0.60 – 0.78), but more likely to have a
dyslipidemia of triglyceride (OR: 1.27, 95% confidence
interval: 1.26 - 1.28). No effect was observed for age.
The result of this analysis is presented in Table 3.
Discussion
The current study described the trend of dyslipidemia
over a six-year period during 2009 to 2014 in NL using
provincial medical laboratory information. The analyses
identified a significant downward trend in the prevalence
of dyslipidemia of LDL-C and HDL-C during this period.
Further evaluations indicated that this declining pattern
is mainly represented in males, whereas females do not
show a significant change in the trend of dyslipidemia.
Being male was also associated with a lower risk of hav-
ing any form of dyslipidemia except for triglyceride.
Dyslipidemia is a highly manageable risk factor for
CVD. The association between hyperlipidemia and the
incidence, morbidity, and mortality of CVD has been re-
ported in numerous studies [19, 20]. Every 1.0 mmol/L
(38.6 mg/dl) reduction in LDL-C is found to be associ-
ated with a ~ 23% relative risk reduction in major vascu-
lar events over a five-year period [21]. Similarly, every 1.
0 mg/dl increase in HDL-C has resulted in a 2-3% re-
duction in the occurrence of coronary heart disease [22].
Guidelines for the management of lipid levels as a means
of CVD risk reduction have been in effect for decades,
and these practices have resulted in a significant de-
crease in the rates of dyslipidemia, and subsequently
CVD, in the developed world. Examination of a 30-year
trend (1976-2006) in serum lipids among adults in the
United States has shown decreases in age-adjusted mean
TC (210 to 200 mg/dl) and LDL-C (134 to 119 mg/dl) as
well as a significant increase in mean HDL-C (50 to
53 mg/dl) [23]. Similar patterns of change have been
observed in Europe, as reported in a 10-year period by
the Framingham Heart Study [24], and the northern
Sweden MONICA study [25]. In Canada, projected rates
Fig. 1 Rates of dyslipidemia by lipid components over six years: TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol, LDL-C: Low-density
lipoprotein cholesterol, TG: Triglycerides
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of high cholesterol, based on the observed rates from
the Canadian Health Measure Survey, indicates a grad-
ual decrease in hypercholesterolemia between 2001 and
2021 [11].
In NL, however, no data is available on the time trend of
change in dyslipidemia, besides the few recent reports of a
higher rate of hypercholesterolemia compared to the rest
of Canada. Our study is the first to examine such a trend
over a six-year period in NL. Approximately ten years ago,
a survey of waist circumference and body mass index in
NL recommended that young NL adults are at an elevated
risk of cardiovascular events due to the distribution of
body fat [26]. Since then, multiple evaluations by our
group and others recommended that the NL population
may also suffer from a higher rate of dyslipidemia and
other CVD risk factors [13]. These reports could have led
to an increased awareness among the clinicians in NL.
The findings in the present study recommend that NL is
at the beginning of a movement toward improving cardio-
metabolic profiles. Our results support a declining trend
in the rates of dyslipidemia of HDL-C, LDL-C, and TC.
However, the level of change is not as significant as those
found elsewhere, and any degree of improvement is re-
stricted to men. These may be an indication of a recent
movement towards the improvement of primary care
management of dyslipidemia in the province.
An interesting finding in this study was that any de-
clining trend in the rates of abnormal lipid profiles is re-
stricted to men. Also, being male was significantly
associated with a lower risk of having any dyslipidemia,
except for TG. These might suggest that men have been
targeted more intensively for CVD risk management. An
alternative explanation might be related to the distribu-
tion of the age of our population. At the mean age of >
55, women are influenced by the physiological changes
of menopause and are likely to show a higher rate of
dyslipidemia [27]. It is possible that due to these physio-
logical changes, women are not as responsive to CVD
risk interventions as men [28, 29]. These hypotheses,
however, will need to be further investigated.
Our study is limited by a few factors which need to be
taken into consideration. The findings are built on the
clinical laboratory tests conducted in the province and
thus may not show a crude prevalence of dyslipidemia in
NL. However, the results represent any individual who has
ever performed a lipid test in the province during the six-
year period, and thus, they can be used as a reliable indi-
cator of population health as related to CVD and dyslipid-
emia. The other limitation of this study is the lack of
information on the confounding factors that might influ-
ence dyslipidemia (e.g., body mass index, diabetes, meno-
pause status and smoking). Also, the information related
to lipid modifying agent consumption was not available.
Lifestyle-related factors related to hypercholesterolemia
such as nutritional behaviors, physical activity and aware-
ness towards primary prevention were not included in this
study since we did not have access to datasets where these
variables were included.
Conclusion
The findings of this study reveal that NL has started to
follow the declining trend in the rates of dyslipidemia.
This is mainly represented as a significant downward
trend in the rates of LDL-C, HDL-C, and TC dyslipid-
emia in men. These trends could be the result of males
being the primary target for cardiovascular risk manage-
ment guidelines; however, further research is required to
verify this hypothesis. The province of Newfoundland
and Labrador could see a reduction in cardiovascular
disease incidence along with their associated mortality
rates following an improvement in lipid profiles within
the next few years. Our study’s findings indicate the ur-
gency for further investigation into this matter which
can be considered essential for the proper surveillance
of chronic disease outcomes in the province.
Abbreviations
CVD: Cardiovascular disease; HDL-C: High-density lipoprotein cholesterol;
LDL-C: Low-density lipoprotein cholesterol; LIS: Laboratory information
system; NL: Newfoundland and Labrador; OR: Odds ratio; TC: Total
cholesterol; TG: Triglyceride
Table 3 Risk of dyslipidemia over the five years after 2009 using a mixed effect model
Variable TC HDL-C LDL-C TG
Year
2010 0.97 (0.95-0.99) 0.92 (0.90-0.94) 0.96 (0.94-0.98) 0.92 (0.90-0.94)
2011 0.95 (0.93-0.97) 0.84 (0.83-0.86) 0.87 (0.85-0.88) 0.98 (0.96-1.00)
2012 0.90 (0.88-0.91) 0.94 (0.92-0.95) 0.88 (0.87-0.90) 0.97 (0.95-0.99)
2013 0.89 (0.88-0.91) 0.83 (0.81-0.84) 0.85 (0.83-0.86) 0.94 (0.92-0.95)
2014 0.96 (0.94-0.98) 0.78 (0.77-0.79) 0.87 (0.85-0.88) 0.95 (0.93-0.97)
Sex (M) 0.60 (0.59-0.60) 0.66 (0.65-0.66) 0.78 (0.77-0.79) 1.27 (1.26-1.28)
Age 0.99 (0.99-0.99) 1.00 (1.00-1.00) 0.98 (0.98-0.98) 1.00 (1.00-1.00)
TC Total cholesterol, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, TG Triglycerides. Figures are odds ratio (95% Confidence
Intervals). Every year is compared to 2009 as the base. Year and individual identifier are incorporated as random effects in the model
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